Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613096 | 0.80 | KDM4E (0.34) | KDM4EMAPTMAPK1CYP1A2CYP2A6 | |
| SCHEMBL366594 | 0.78 | ALDH1A1 (0.48) | KDM4EMAPTCYP1A2CYP2A6TSHR | |
| SCHEMBL57999 | 0.78 | MAPT (0.33) | KDM4EMAPTMAPK1CYP1A2CYP2A6 | |
| SCHEMBL3514534 | 0.78 | KDM4E (0.33) | KDM4EMAPTMAPK1CYP1A2CYP2A6 | |
| SCHEMBL16957541 | 0.78 | KDM4E (0.38) | KDM4EMAPTMAPK1CYP1A2CYP2A6 | |
| SCHEMBL5494672 | 0.77 | TSHR (0.45) | KDM4EMAPTMAPK1CYP1A2CYP2A6 | |
| SCHEMBL37955 | 0.77 | TSHR (0.45) | KDM4EMAPTMAPK1CYP1A2CYP2A6 | |
| SCHEMBL1611471 | 0.76 | KDM4E (0.32) | KDM4EMAPTMAPK1CYP1A2CYP2A6 | |
| SCHEMBL3306781 | 0.74 | TRPA1 (0.46) | KDM4EMAPTCYP1A2CYP2A6TSHR | |
| Hydrochloric Acid SCHEMBL11018653 | 0.74 | KDM4E (0.31) | KDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176448-A1 | Mitochondria protecting agents for treating mitochondria associated diseases | MITOKOR (US) | 2003-09-18 | — | — | US | disclosed |
| US-6511966-B2 | Administering for therapy of mitochondria medited disease | MITOKOR | 2003-01-28 | — | — | US | disclosed |
| US-6498191-B2 | FOR TREATMENT OF ALZHEIMER'S DISEASE, DIABETES MELLITUS, PARKINSON'S DISEASE, NEURONAL AND CARDIAC ISCHEMIA, HUNTINGTON'S DISEASE, STROKE | MITOKOR | 2002-12-24 | — | — | US | disclosed |
| EP-1222920-A2 | Mitochondria protecting agents for treating mitochondria associated diseases | MITOKOR (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020068750-A1 | Mitochondria protecting agents for treating mitochondria associated diseases | GHOSH SOUMITRA S (US) | 2002-06-06 | — | — | US | disclosed |
| US-20020065298-A1 | Mitochondria protecting agents for treating mitochondria associated diseases | GHOSH SOUMITRA S (US) | 2002-05-30 | — | — | US | disclosed |
| US-20020065299-A1 | Mitochondria protecting agents for treating mitochondria associated diseases | GHOSH SOUMITRA S (US) | 2002-05-30 | — | — | US | disclosed |
| US-20020010195-A1 | Mitochondria protecting agents for treating mitochondria associated diseases | GHOSH SOUMITRA S (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1051165-A2 | MITOCHONDRIA PROTECTING AGENTS FOR TREATING MITOCHONDRIA ASSOCIATED DISEASES | Mitokor (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037294-A2 | MITOCHONDRIA PROTECTING AGENTS FOR TREATING MITOCHONDRIA ASSOCIATED DISEASES | MITOKOR (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065298-A1 | Mitochondria protecting agents for treating mitochondria associated diseases | TFAM, HSPA9, HSPD1 | KDM4E 4364/4885MAPT 284/4885MAPK1 3521/4885 |
| US-20030176448-A1 | Mitochondria protecting agents for treating mitochondria associated diseases | TFAM, HSPA9, HSPD1 | KDM4E 4356/4885MAPT 283/4885MAPK1 3540/4885 |
| US-20020068750-A1 | Mitochondria protecting agents for treating mitochondria associated diseases | TFAM, HSPA9, HSPD1 | KDM4E 4384/4885MAPT 285/4885MAPK1 3548/4885 |
| US-20020010195-A1 | Mitochondria protecting agents for treating mitochondria associated diseases | TFAM, HSPA9, HSPD1 | KDM4E 4364/4885MAPT 284/4885MAPK1 3521/4885 |
| US-20020065299-A1 | Mitochondria protecting agents for treating mitochondria associated diseases | TFAM, HSPA9, HSPD1 | KDM4E 4366/4885MAPT 284/4885MAPK1 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.